ImmunoPrecise Antibodies Stock (NASDAQ:IPA)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.40

52W Range

$0.33 - $2.60

50D Avg

$0.45

200D Avg

$0.88

Market Cap

$12.58M

Avg Vol (3M)

$565.92K

Beta

0.27

Div Yield

-

IPA Company Profile


ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

72

IPO Date

Jan 07, 2002

Website

IPA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceApr 24Apr 23Apr 22
Product Sales$2.04M$1.75M$1.65M
Project Revenue$22.23M$18.68M$17.36M

Fiscal year ends in Apr 23 | Currency in CAD

IPA Financial Summary


Apr 23Apr 22
Revenue$20.66M$19.36M
Operating Income$-27.95M$-15.78M
Net Income$-26.56M$-16.71M
EBITDA$-21.26M$-12.12M
Basic EPS-$-0.85
Diluted EPS-$-0.85

Fiscal year ends in Apr 23 | Currency in CAD

Latest Earnings Call Transcripts


Q2 25Dec 10, 24 | 5:33 PM
Q1 25Sep 16, 24 | 1:46 PM
Q4 24Jul 29, 24 | 8:36 PM

Peer Comparison


TickerCompany
CUECue Biopharma, Inc.
IPSCCentury Therapeutics, Inc.
AVTEAerovate Therapeutics, Inc.
DRMADermata Therapeutics, Inc.
TCRXTScan Therapeutics, Inc.
RXRXRecursion Pharmaceuticals, Inc.
ANNXAnnexon, Inc.
WVEWave Life Sciences Ltd.
CSBRChampions Oncology, Inc.
TFFPTFF Pharmaceuticals, Inc.
INABIN8bio, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
ZURAZura Bio Limited
STTKShattuck Labs, Inc.
UBXUnity Biotechnology, Inc.
AVIRAtea Pharmaceuticals, Inc.
CGTXCognition Therapeutics, Inc.